Form 4: Jazz Pharma CEO Gains 18,808 Shares via RSU Grant

Jazz Pharmaceuticals plc's President and CEO, Renee D. Gala, reported the acquisition of 18,808 ordinary shares through a restricted stock unit grant and 166 shares via an employee stock purchase plan.

Summary

• Renee D. Gala, President & CEO of Jazz Pharmaceuticals plc, reported changes in her beneficial ownership.
• She acquired 18,808 ordinary shares through a restricted stock unit (RSU) grant on August 7, 2025.
• These RSUs were granted under the Issuer's 2011 Equity Incentive Plan and represent a contingent right to receive one ordinary share per unit upon vesting.
• The RSUs will vest in equal annual installments over four years, commencing in September 2025.
• Additionally, Ms. Gala acquired 166 ordinary shares on May 30, 2025, under a Section 423 Employee Stock Purchase Plan.
• Following these transactions, her total beneficial ownership stands at 107,869 ordinary shares.

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a key executive, aligning management incentives with shareholder interests, which is generally a positive sign for corporate governance and stability. It does not contain any negative news or risks.

Positives

• Grant of 18,808 restricted stock units to the President & CEO aligns management incentives with shareholder interests.
• Acquisition of 166 shares through an Employee Stock Purchase Plan indicates management's continued investment in the company.

Future Outlook

The 18,808 restricted stock units granted to the President & CEO are scheduled to vest in equal annual installments over four years, commencing in September 2025.

Industry Context

This is a standard executive compensation event in the pharmaceutical industry, where equity grants are common for aligning executive interests with long-term company performance.

Comparison to Industry Standards

• Equity-based compensation, particularly through restricted stock units and employee stock purchase plans, is a common practice across the pharmaceutical and biotechnology sectors for executive and employee retention and motivation.
• The vesting schedule of four years for RSUs is typical for long-term incentive plans in companies like Pfizer, Merck, or Johnson & Johnson, aiming to ensure sustained executive commitment.
• The specific number of shares granted would need to be compared against the executive's total compensation package and peer group compensation data for a full assessment, which is not provided in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns the President & CEO's interests with long-term shareholder value.
• Employees: The Employee Stock Purchase Plan (ESPP) indicates a benefit available to employees, fostering broader employee ownership.

Next Steps

• Vesting of 1/4th of the 18,808 restricted stock units on the first anniversary of the September 2025 vesting commencement date.
• Subsequent vesting of the remaining restricted stock units in equal annual installments over the following three years.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation event for a senior executive. It does not contain information about the company's financial performance, strategic direction, or market-moving news that would warrant a change in investment recommendation. It primarily reflects standard corporate governance and executive incentive alignment.

Keywords

Jazz Pharmaceuticals, JAZZ, Renee D Gala, Form 4, SEC Filing, Insider Trading, Restricted Stock Units, RSU, Employee Stock Purchase Plan, ESPP, Equity Incentive Plan, Executive Compensation, Share Ownership